FCPM III SERVICES B.V.
CIK
2013410
Location
NAARDEN, P7
Portfolio Value
Small
$714,925,124
Diversification
Moderately concentrated
Filing Date
Global Rank
#2,126
/ 8,603
▲ 117
· as of Mar 2026
Top Industry
Biotechnology
100.0%
3Y Alpha vs SPY
-10.1%
Period ended 3 months ago
Filed May 15, 2026 · 55d
10 quarters · since Dec 2023
Clone Performance
Feb 2024–Jul 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+28.3%
SPY
+54.1%
Annualised alpha
-8.8%
Max drawdown
−57.6%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
9 positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
41.2%
−5.4 pts
Top 5
81.6%
−8.0 pts
Top 10
100.0%
0.0 pts
HHI
2,220
Moderately concentrated−499
Portfolio Trend
10 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $714,925,124 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| VOR | Vor Biopharma Inc. | +500,000 | 4,117,354 | $73,453,595 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | −818,460 | 4,644,386 | $84,202,718 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | 2,441,000 | $63,221,900 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exitedNo qualifying positions this quarter.
9 positions ·
$714,925,124 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| NAMS |
NewAmsterdam Pharma Co N.V.
Healthcare
|
Held | 9,198,900 | $294,456,788 | 41.19% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Reduced | 4,644,386 | $84,202,718 | 11.78% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Added | 4,117,354 | $73,453,595 | 10.27% | |
| ENGN |
enGene Therapeutics Inc.
Healthcare
|
Held | 9,632,561 | $65,597,740 | 9.18% | |
| MPLT |
MapLight Therapeutics, Inc.
Healthcare
|
Held | 3,226,400 | $65,592,712 | 9.17% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
NEW | 2,441,000 | $63,221,900 | 8.84% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 1,677,852 | $30,822,141 | 4.31% | |
| REPL |
Replimune Group, Inc.
Healthcare
|
Held | 2,808,368 | $21,484,015 | 3.01% | |
| BCYC |
Bicycle Therapeutics PLC
Healthcare
|
Held | 3,468,430 | $16,093,515 | 2.25% |